Get started
Author

Jeffrey Victor Leyton

Observed names: J. V. Leyton, J.V. Leyton, Jeffrey Leyton, Jeffrey V Leyton, Jeffrey V. Leyton, Leyton, Jeffrey V., Victor Jeffrey Leyton
Observed institutions: Université de Sherbrooke, University of Ottawa, University of California, Los Angeles, University of Toronto, Centre Hospitalier Universitaire de Sherbrooke, Institut de pharmacologie de Sherbrooke
ORCID: 0000-0001-6870-3819
Observed ORCID: 0000-0001-6870-3819
OpenAlex ID: A5031022558
Solution-Phase Surface Modification in Intact Poly(dimethylsiloxane) Microfluidic Channels
2006 · Guodong Sui, Jinyi Wang, et al. · Analytical Chemistry · 238
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
2021 · Manar Hammood, Andrew Craig, et al. · Pharmaceuticals · 130
PDF
Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody
2007 · Tove Olafsen, Zhennan Gu, et al. · Journal of Immunotherapy · 70
Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors
2008 · Jeffrey V. Leyton, Tove Olafsen, et al. · Clinical Cancer Research · 68
Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
2019 · Brent A. Williams, Arjun Law, et al. · Journal of Clinical Medicine · 57
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
2010 · Eric J. Lepin, Jeffrey V. Leyton, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 57
PDF
111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer
2012 · Aisha Fasih, Humphrey Fonge, et al. · Breast Cancer Research and Treatment · 55
Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
2020 · Olga Bednova, Jeffrey V. Leyton · International Journal of Molecular Sciences · 52
PDF
Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131− Phenotype of the Leukemia Stem Cell Population
2011 · Jeffrey Victor Leyton, Meiduo Hu, et al. · Journal of Nuclear Medicine · 46
PDF
Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
2008 · J. V. Leyton, T. Olafsen, et al. · Protein Engineering Design and Selection · 43
PDF
Nuclear localization signal-tagged systems: relevant nuclear import principles in the context of current therapeutic design
2023 · Ritabrita Goswami, Aarohi Gupta, et al. · Chemical Society Reviews · 34
PDF
Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
2020 · Jeffrey Leyton · Antibodies · 31
PDF
The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 111In-NLS-7G3 radioimmunoconjugates
2014 · Arman Zereshkian, Jeffrey V. Leyton, et al. · Nuclear Medicine and Biology · 30
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
2018 · Brent A. Williams, Xing-Hua Wang, et al. · Haematologica · 27
ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation
2016 · Simon Beaudoin, Andreanne Rondeau, et al. · Molecular Pharmaceutics · 25
Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer
2017 · Michel Paquette, Luis-Guillermo Vilera-Perez, et al. · OncoImmunology · 21
PDF
BODIPY-17α-ethynylestradiol conjugates: Synthesis, fluorescence properties and receptor binding affinities
2016 · Samira Osati, Hasrat Ali, et al. · Bioorganic & Medicinal Chemistry Letters · 20
A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML
2015 · Jeffrey V. Leyton, Catherine Gao, et al. · Leukemia Research Reports · 20
PDF
The endosomal-lysosomal system in ADC design and cancer therapy
2023 · Jeffrey V. Leyton · Expert Opinion on Biological Therapy · 18
A Novel Proteomic Method Reveals NLS Tagging of T-DM1 Contravenes Classical Nuclear Transport in a Model of HER2-Positive Breast Cancer
2020 · Vincent Lacasse, Simon Beaudoin, et al. · Molecular Therapy — Methods & Clinical Development · 18
PDF
MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131− epitope expressed by leukemia stem cells
2014 · Jeffrey V. Leyton, Brent Williams, et al. · Leukemia Research · 18
NLS-Cholic Acid Conjugation to IL-5Rα-Specific Antibody Improves Cellular Accumulation and In Vivo Tumor-Targeting Properties in a Bladder Cancer Model
2018 · Michel Paquette, Simon Beaudoin, et al. · Bioconjugate Chemistry · 15
Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123 + /CD131 − phenotype of leukemia stem cells
2015 · Catherine Gao, Jeffrey V. Leyton, et al. · Applied Radiation and Isotopes · 15
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
2025 · Negar Pourjamal, Vadim Le Joncour, et al. · Translational Oncology · 11
Paradoxical effects of Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45 + cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice
2016 · Dane Bergstrom, Jeffrey V. Leyton, et al. · Nuclear Medicine and Biology · 9
Works count: 48
Citation count: 1,161
H-index: 18
I10-index: 24
Year
Topic
Type